93 related articles for article (PubMed ID: 16926249)
1. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
Paisley AN; O'Callaghan CJ; Lewandowski KC; Parkinson C; Roberts ME; Drake WM; Monson JP; Trainer PJ; Randeva HS
J Clin Endocrinol Metab; 2006 Nov; 91(11):4635-40. PubMed ID: 16926249
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
3. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
Parkinson C; Burman P; Messig M; Trainer PJ
J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals.
Randeva HS; Lewandowski KC; Komorowski J; Murray RD; O'Callaghan CJ; Hillhouse EW; Stepien H; Shalet SM
Circulation; 2004 May; 109(20):2405-10. PubMed ID: 15123527
[TBL] [Abstract][Full Text] [Related]
5. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
[TBL] [Abstract][Full Text] [Related]
8. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
9. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of vascular endothelial growth factor in patients with acromegaly.
Nagai Y; Ando H; Nohara E; Yamashita H; Takamura T; Kobayashi K
Horm Metab Res; 2000 Aug; 32(8):326-9. PubMed ID: 10983629
[TBL] [Abstract][Full Text] [Related]
13. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly.
Madsen M; Fisker S; Feldt-Rasmussen U; Andreassen M; Kristensen LØ; Ørskov H; Jørgensen JO
Clin Endocrinol (Oxf); 2014 Jan; 80(1):92-100. PubMed ID: 23650996
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
16. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
17. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
[TBL] [Abstract][Full Text] [Related]
19. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
Jehle S; Reyes CM; Sundeen RE; Freda PU
J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly.
Jimenez C; Ayala-Ramirez M; Liu J; Nunez R; Gagel RF
Horm Metab Res; 2011 Jan; 43(1):55-61. PubMed ID: 21104581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
